ALK is an inclusion eligibility criterion in 3 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 3 are open and 0 are closed. Of the trials that contain ALK status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 3 (2 open) [3].

BCL2 is altered in 22.22% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [2].

BCL2 is an inclusion eligibility criterion in 24 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 24 are open and 0 are closed. Of the trials that contain BCL2 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 5 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is no phase specified (1 open) [3].

BCL6 is altered in 55.56% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [2].

BCL6 is an inclusion eligibility criterion in 24 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 24 are open and 0 are closed. Of the trials that contain BCL6 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 5 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is no phase specified (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains IGH status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 11.11% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [2].

MYC is an inclusion eligibility criterion in 24 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 24 are open and 0 are closed. Of the trials that contain MYC status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 5 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is no phase specified (1 open) [3].